Adcetris brentuximab vedotin regulatory update

The European Commission approved an expanded label for Adcetris brentuximab vedotin from Takeda to include treatment of adults with CD30-positive Hodgkin’s lymphoma (HL) at increased risk of relapse or progression following autologous stem cell transplantation (ASCT). The product is approved in the EU to treat adults with relapsed or refractory CD30-positive HL following ASCT or following >=2 prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. It is also approved to treat relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). ...